tirzepatide 15mg/ml (15mg Vial) Tirzepatide Injection - MOUNJARO 15

Someone with a BMI of 40 who needs to lose 80 pounds will need more time than someone at BMI 32 targeting 30 pounds

Five studies evaluated semaglutide and one tirzepatide

The subcutaneous formulation allows for convenient once-weekly dosing, making adherence to medication regimes easier for patients

This drug, with promising results for NASH-related biomarkers, 55 is under evaluation in a phase 2 study (SYNERGY-NASH, NCT04166773), with the primary outcome being the absence of NASH and no worsening of fibrosis on liver histology after 1 year of treatment

Safety assessment is paramount in dose escalation decisions